| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_122650eb52acea73f51909f275549e74 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62ca9ff88b0fdfcce2180fa615a67c83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3cd497427258c7d268825da46f204f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3969074f853cf2d1bcf8c95aed85e180 |
| publicationDate |
2009-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009220523-A1 |
| titleOfInvention |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
| abstract |
The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine-1-phosphate (S1P) or lysophosphophatidic acid (LPA). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010226916-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8614103-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009074789-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023109982-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8444970-B2 |
| priorityDate |
2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |